Our JCCT team has completed over 300 clinical trials – including more than 200 vaccine trials – making us one of the most qualified vaccine-focused, full-service clinical research sites. With in-depth experience in Phases I-IV (outpatient and inpatient) and more than 50 first-in-human clinical trials, we adhere to the highest standards in accuracy, safety, timeliness, ethics, and service for every trial, sponsor, and participant.
We have been involved in the development of 23 new or improved drugs and vaccines brought to market, including those funded by the Department of Defense, BARDA, the National Institutes of Health, and the Division of Microbiology and Infectious Diseases.
Our people represent some of the best in the industry. Our Clinical Operations Team includes approximately 60 clinicians – physicians, nurse practitioners, registered nurses, pharmacists, respiratory therapists, and other health care professionals. Together, our Chief Medical Officer/Principal Investigator, our sub-investigators, and our consultants in cardiology, endocrinology, nephrology, and neurology have over 50 years’ combined experience in clinical research.
We have four in-house pharmacists with a combined total of over 20 years of experience, as well as dedicated departments for medical, nursing, recruiting, study management, quality, laboratory, on site Peripheral Blood Mononuclear Cell (PBMC) Isolation and data management.
Specialized Expertise
Our team also specializes in the following areas:
- Numerous pathogens
- Platforms
- Adjuvants
- Routes of delivery
- Signals of special interest including:
- Corrected QT Interval (QTc)
- Neurologic signs/symptoms
- Other Adverse Events of Special Interest (AESI)
View a sampling of studies we’ve conducted.
Some of the studies we’ve conducted include:
- COVID
- Anthrax
- Chikungunya
- H5N1
- CMV
- Zika
- Cholera
- H3N2
- RSV
- Meningococcal
- Anti-orthopoxvirus
- Norovirus
- Hepatitis B
- Group B Streptococcus
- Dengue
- Yellow Fever
- Smallpox
- Pandemic flu
- Seasonal flu
- Botulinum toxin
- Plague vaccines
Completed Vaccine Trials
We are proud to have been part of bringing the following innovation to market.
Approved vaccines
- mRESVIA, approved 2024 – Moderna
- ABRYSVO, approved 2023 – Pfizer, Inc.
- AREXVY, approved 2023 – GSK
- CYFENDUS, approved 2023 – Emergent BioSolutions
- SPIKEVAX, approved 2022 – Moderna
- COMIRNATY, approved 2021 – BioNTech
- Fluad Quadrivalent, approved 2020 – Seqirus
- JYNNEOS, approved 2019 – Bavarian Nordic
- Tecovirimat (TPOXX), approved 2018 – Siga
- HEPLISAV-B, approved 2017 – Dynavax
- SHINGRIX, approved 2017 – GSK
- Flucelvax Quadrivalent, approved 2016 – Novartis/Seqirus
- AFLURIA QUADRIVALENT, approved 2016 – Seqirus
- VAXCHORA, approved 2016 – Emergent Travel Health
- Fluad, approved 2015 – Seqirus
- BioThrax® (Anthrax Vaccine Adsorbed), approved 2015 (recent changes to indication, usage, administration, and dosage) – Emergent BioSolutions
- Q-Pan H5N1, approved 2013 – GSK
- Fluzone, approved 2013 – Sanofi
- Flucelvax, approved 2012 – Novartis/Seqirus
- CERVARIX, approved 2009 – GSK
- High Dose Fluzone, approved 2009 – Sanofi
- ACAM2000, approved 2007 – Acambis / Sanofi
- FLULAVAL, approved 2006 – GSK
